Who is sponsoring NCT00423189?

NCT00423189 is sponsored by David M. Brown, M.D..

What condition does NCT00423189 study?

NCT00423189 studies Age-Related Macular Degeneration.

What drugs are being tested in NCT00423189?

Interventions: Ranibizumab (Lucentis), 0.5mg ranibizumab.

What is the status of NCT00423189?

NCT00423189 is currently TERMINATED.

Last reviewed 2016-02-05 · How we verify

Lucentis Utilizing Visudyne (LUV Trial)-- Reduced Fluence Photodynamic Therapy With Visudyne Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration

NCT00423189 Phase 4 TERMINATED Results posted

The PDT/Lucentis trial will be a Phase IV comparative trial comparing the use of combination therapy with ITV ranibizumab and verteporfin PDT to ITV ranibizumab alone in patients with exudative AMD.

Details

Lead sponsor	David M. Brown, M.D.
Phase	Phase 4
Status	TERMINATED
Enrolment	7
Start date	2007-01
Completion	2009-01

Conditions

Age-Related Macular Degeneration

Interventions

Ranibizumab (Lucentis)
0.5mg ranibizumab

Primary outcomes

Best-corrected ETDRS Visual Acuity at 6 Months and 12 Months Only Time Points (Gain or Loss of >15 Letters at 12 Months) — 1 Year
Visual Acuity was measured by ETDRS by certified refractionists in certified lanes at 12 months. Visual Acuity was not measured by ETDRS at 6 months.

Countries

United States